Human epidermal growth factor receptor 2 (HER2) is one of the key molecular targets in
breast cancer pathogenesis. Overexpression and/or amplification of HER2 in approximately …

Objective Endoscopic mucosal biopsies of primary gastric cancers (GCs) are used to guide
diagnosis, biomarker testing and treatment. Spatial intratumoural heterogeneity (ITH) may …

Simple Summary Existing chemotherapy treatments for breast cancer patients are high on
toxicity. There are very limited options available for triple-positive breast cancer (TPBC) …

Targeted therapies have come to play an increasingly important role in cancer therapy over
the past two decades. This success has been made possible in large part by technological …

Breast cancer is one of the most frequently diagnosed cancers in women and the major
cause of worldwide cancer-related deaths among women. Various treatment strategies …

Background The phenotypes of tumor cells change during disease progression, but invasive
rebiopsies of metastatic lesions are not always feasible. Here we aimed to determine …

HER2‐positive breast cancer is an aggressive subtype that typically responds poorly to
standard chemotherapy. To design an anticancer drug selective for HER2‐expressing …

Breast cancer is one of the most leading causes of death for women worldwide. According to
statistics published by the International Agency for Research on Cancer (IARC), the …

Rationale: Resistance to targeted therapies like trastuzumab remains a critical challenge for
HER2-positive breast cancer patients. Despite the progress of several N-terminal HSP90 …

Breast cancer (BC) is caused by epigenetic modifications and genetic heterogeneity and
exhibits various histological feature. HER2+ (Human epidermal growth factor receptor 2) is a …